Abstract. Amyloid fibril protein in patients with familial amyloidotic polyneuropathy is known to be chemically related to transthyretin (TTR), the plasma protein that is usually referred to as prealbumin. A genetically abnormal TTR may be involved in this disease. (Saraiva, 
Introduction
The heredofamilial amyloidoses represent a heterogeneous group of genetic syndromes that are defined by the presence of extracellular deposits of insoluble fibrillar protein. Most of these syndromes are characterized by the appearance of peripheral neuropathy, and are transmitted in an autosomal dominant manner (1) .
In 1978, Costa et al. (2) presented evidence that the amyloid deposits in the Portuguese variety of familial amyloidotic polyneuropathy (FAP)' contain a protein related to transthyretin (TTR; usually referred to as prealbumin)2 as a major constituent. Subsequently, TTR-related protein was found to be associated with amyloid deposits in patients with FAP from several countries and ethnic origins (3) (4) (5) (6) (7) . It was suggested (2) that in FAP a genetic mutation in TTR may have occurred, leading to the production of an abnormal TTR, which is abnormally bound, degraded, and/or precipitated in tissues as amyloid fibrils. To explore this hypothesis, we recently conducted studies designed to investigate whether Portuguese patients with FAP have an abnormal species of TTR circulating in their plasma (8) . Human TTR is a protein of 54,980 Mr, composed of four identical subunits (9) . TTR forms a stable complex with plasma retinol-binding protein (RBP), which is the specific transport protein for retinol (10) , and is involved in the plasma transport of both thyroid hormone and retinol (vitamin A) (1 1). Significantly reduced levels of TTR were found in patients with FAP (8) . TTR was isolated from serum of FAP patients and was examined in detail. FAP-TTR was indistinguishable from normal TTR with regard to a wide range of physical and chemical properties (8) .
Since FAP-TTR and normal plasma TTR (N-TTR) were indistinguishable with regard to these physical-chemical characteristics, it became apparent that further progress towards the biochemical definition ofthe abnormality in FAP would require the study of the TTR-related amyloid protein from the tissues. Accordingly, the present study was undertaken with the goal of isolating purified amyloid fibril protein and then of conducting detailed studies of its chemical structure and physical properties, in comparison to those of TTR.
We now report studies on the primary structure of the purified amyloid fibril protein from Portuguese patients with FAP (AFp),3 compared with that of plasma TTR from patients with FAP and from normal persons. The amyloid fibril protein used in this work was purified by a novel procedure, and was characterized with regard to a number of physical-chemical prop- erties. The present studies indicate that there is a methioninefor-valine substitution at position 30 in the AFp as compared with normal plasma TTR. The variant TTR is also present in plasma of FAP patients, together with a larger amount of normal TTR. The results of this work have been reported previously in abstract form (12).
Methods
Purified TTR and AFp. TTR was isolated from pooled serum from 24 patients with FAP, and from normal plasma, as described in detail previously (8) . The (FAP-TTR and N-TTR) were the same preparations of TTR previously used in the comparative study of some of the physical and chemical properties of FAP-TTR and N-TTR (8) .
AFp was isolated from amyloid fibril concentrates that were obtained postmortem from the kidneys of two Portuguese patients with type I FAP. The first patient (case XII), a woman who died at age 41, had a typical family history, and a characteristic clinical picture (13) , which began at age 27. Paresis of the extremities (particularly the lower ones) and gastrointestinal disturbances were prominent; these symptoms progressed over several years, and were followed by cachexia and death.
Several members of the family of the second patient (case XIV), a man who died at age 43, were affected in four generations. At age 32 case XIV developed impaired thermal and pain sensation in the lower extremities. The diagnosis of FAP was confirmed by a positive nerve biopsy. The patient died after a progressive and typical evolution of his disease.
Amyloid fibrils were purified by repeated homogenization in phosphate-buffered saline, and then in distilled water, in a modification of the methods of Pras et al. (14) and Glenner et al. (15) , as described previously (2) . The lyophilized amyloid fibril concentrates were solubilized and reduced with dithiothreitol in 6 M guanidine-HCl, which was followed by alkylation with iodoacetic acid. These procedures were carried out as follows: First, 120 mg of lyophilized amyloid fibril concentrate was dispersed and solubilized in a solution of 6 M guanidine-HCl, 1 M Tris-HCl, 1 mM EDTA, and 20 mM dithiothreitol, pH 8.8, for 3 h at 370C. Undissolved material was removed by centrifugation at 105,000 g for 1 h. To the clear supernatant, 36 mg iodoacetic acid was added, and alkylation was allowed to proceed for 15 min at room temperature in the dark at pH 6.9. The sample was then applied to a column of Bio-gel P-10 (Bio-Rad Laboratories, Richmond, CA) and equilibrated in a solution of 5 M guanidine-HCl, 0.1 M Tris, 4 mM EDTA, pH 8.6, to remove excess iodoacetic acid. The resulting solution was dialyzed against distilled water and lyophilized. Purified AFp was obtained from this solution by affinity chromatography on RBP linked to Sepharose. Affinity chromatography. Human RBP covalently linked to Sepharose was prepared as an affinity support. The human RBP used was the same preparation of RBP previously used in studies ofthe amino acid sequence of RBP reported by Kanda and Goodman (16) . The RBP had been isolated from the urine of Japanese patients with chronic cadmium poisoning and tubular proteinuria, and had been stored in the lyophilized state at -20°C. A sample (17 mg) ofthis RBP was saturated with retinol, by addition of an excess of all-trans-retinol in ethanol to an aqueous solution of RBP, followed by gel filtration to remove unbound retinol, as described previously (17). The resulting preparation, consisting mainly of holo-RBP (the retinol-RBP complex) was coupled to 3 g of CNBractivated Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, NJ), according to the manufacturer's instructions and following established principles (18) . The yield of coupled RBP was >90%.
The reduced and alkylated amyloid preparation (see above) was dissolved in 3 ml of 50 mM Tris-HCl buffer, pH 7.4, containing 0.15 M NaCI, and was then applied to a column of RBP-Sepharose (1 X 10 cm), which was equilibrated with the same buffer. Elution with this buffer resulted in elution of material that did not bind to the gel. After such material was completely eluted, and no more protein appeared in the effluent, the buffer was replaced with distilled water adjusted with NH40H to pH 10.4, in order to elute protein bound to the column. It is known that the RBP-TTR complex dissociates in solutions of very low ionic strength and at alkaline pH ( 19, 20) . The fractions containing eluted "bound" protein were pooled, dialyzed against distilled water, and lyophilized. For each assay mixture, a paired assay mixture containing an excess (4 X 10-6 M) of unlabeled T4 (Calbiochem-Behring Corp., La Jolla, CA) was also set up, in order to examine displacement of labeled T4 from specific binding sites. After incubation for 30 min at room temperature, the assay tubes were chilled to 0C, and protein-bound ['25I1T4 was isolated by gel filtration on minicolumns of Sephadex G-25, which were equilibrated with Tris buffer. Fractions of 0.12 ml were collected.
Free hormone (T4) bound tightly to the gel matrix and was eluted later with 0.25 N NaOH (fractions of 1 ml each). Portions of all fractions were assayed for '25I in a Packard model 5022 gamma counter (Packard Instrument Co., Inc., Downers Grove, IL). The radioactive fractions corresponding to the peak of protein-bound T4 were subjected to polyacrylamide gel electrophoresis (PAGE). The resulting gels were sliced from top to bottom in 2-mm thick slices, and the radioactivity (1251) in each slice was assayed in the same gamma counter.
Modification reactions. N-TRR and FAP-TTR were reduced and carboxymethylated with [3H]iodoacetic acid (New England Nuclear) by a modification of the method of Crestfield as previously described (22) . Unbound iodoacetic acid was removed by dialysis against 0.1 M ammonium acetate buffer, pH 6.8.
Proteolysis with trypsin. Digestions with trypsin (treated with N-tosyl-phenylalanine chloromethyl ketone) (Worthington Biochemical Corp., Freehold, NJ) were carried out at pH 8.4 in 1 M NH4HCO3, with an enzyme/substrate ratio (wt/wt) of 1:100. The reaction was stopped by the addition ofan equal volume of 1 N HCI, followed by Iyophilization. In most instances, the proteolytic reaction was carried out for 90 min, with trypsin being added at time 0 and after 45 min of digestion.
Cyanogen bromide cleavage. Cleavage with CNBr (Pierce Chemical Co., Rockford, IL) was effected in 70% formic acid, for 24 h at room temperature, with a protein concentration of 5 mg/ml, by using a 300-fold molar excess of reagent (23 Tryptic peptide mapping was carried out by separating the tryptic peptides by using two different solvent systems at different pHs. In most instances, the peptides were separated in a phosphoric acid/acetonitrile system (system 1), pH 2.0, and were detected by ultraviolet light absorbance. In other experiments, a trifluoroacetic acid (TFA)/propanol, pH 4.0, system, (system 2), with postcolumn fluorescence derivatization detection, was used (24) .
Conditions for system 1 were as follows: Solvent A was 0.1% phosphoric acid and solvent B was the same in 50% acetonitrile. Absorbances at 220 and 280 nm were monitored at a flow rate of I ml/min. A gradient from 0 to 100% solvent B in 90 min was used as follows: 5 min isocratic buffer A, a linear gradient from 0 to 60% B in 65 min, and 10 min isocratic elution with 60% B. Finally, after a 10-min linear gradient to 100% B, a 5-min isocratic elution in 100% B eluted undigested TTR. When necessary, the peptides were further separated by rechromatography on the same column, using 0.1% TFA, titrated to pH 4.0 with triethylamine (Pierce Chemical Co., sequanal grade), as solvent A and the same buffer in 50% 2-propanol, as solvent B. This system was called system la. Absorbance was monitored at 230 and 280 nm; a linear gradient from 30 to 60% solvent B in 40 min was used at a flow rate of 0.5 ml/min.
Conditions for system 2 were as follows: Solvent A was 0.1% TFA, titrated to pH 4.0 with pyridine, and solvent B was the same in 50% 2-propanol. A gradient for 50 min from 0 to 60% solvent B, at a flow rate of0.6 ml/min was used. The peptides were detected by fluorometry, after reaction with o-phthaldialdehyde (o-PA) in the presence of mercaptoethanol (25) . The reagent was prepared according to the instructions ofthe supplier (Pierce Chemical Co.). For preparative purposes, a streamsplitting system (24) was used. Amino acid analysis by HPLC, using automatic precolumn fluorescence derivatization (Waters Associates, Inc., Technical Bulletin, November 1982) was also used for the identification of individual amino acids, following Edman degradation or carboxypeptidase digestion (see below). After reaction with o-PA in the presence of mercaptoethanol, the fluorescent amino acid derivatives were separated by HPLC on a 5-,Mm reverse-phase C18 radial compressed column (Waters Associates) with gradient elution development. The separation ofthe standard amino acids (Pierce Chemical Co.) was achieved with conditions similar to those described by Hill et al. (27) 
Results
Isolation ofAF, by affinity chromatography on RBP-Sepharose.
Previous work had shown that the amyloid fibrils from tissues of Portuguese patients with FAP contain a protein related to TTR that is not found in identically treated tissue preparations from normal humans (2) . TTR is known to bind with high affinity to RBP (10, 11, 19, 20) , and to form a stable TTR-RBP protein-protein complex. Moreover, our earlier studies showed that plasma TTR from patients with FAP bound to RBP with a capacity and affinity that were similar to that seen with normal TTR (8 After solubilization of the whole fibril preparation in 6 M guanidine, the preparation was alkylated with iodoacetic acid (see Methods) . Previous studies have shown that reduction and alkylation of TTR do not affect its binding properties for RBP (35) . The alkylated preparation was dialyzed to remove guanidine and was then Iyophilized. The resulting preparation dissolved in the buffer used for affinity chromatography, in the absence of guanidine or of any detergent. Fig. I shows the elution profile obtained after passage of the whole fibril preparation through a column of RBP linked to Sepharose. A major peak (peak I) of material that did not bind to the support was eluted with the void volume. When all unbound material had been completely eluted, the buffer was changed to distilled water at pH 10.4. This resulted in the elution Figure 1 . Affinity chromatography of a solubilized FAP amyloid fibril preparation on a column of human RBP linked to Sepharose 4B. Reduced and alkylated amyloid fibril material (120 mg) was solubilized in 3 ml 0.05 M Tris-HCl buffer, pH 7.4, containing 0.15 M NaCi, and applied to the affinity column. Fractions of 2 ml were collected at a rate of -15 ml/h. At the position indicated in the figure by an arrow, the buffer was changed to distilled water at pH 10.4. Fractions 2 through 20 (referred to as peak 1) and fractions 30 through 34 (designated peak II) were each combined, dialyzed against water, and lyophilized.
of a peak of protein (peak II) that had bound to the affinity support. About 20% of the total protein applied to the column was eluted in this peak. An identical affinity chromatography procedure has been used for the isolation of TTR from serum (36).
The peak II material migrated as a single protein band on PAGE. A single band of -14,000 mol wt was also observed on SDS-PAGE, under dissociating conditions. Thus, peak II protein represented a purified AFp.
Properties of the purified AF,. To compare the mobilities of the AFp (the peak II protein) and normal plasma TTR (which had also been carboxymethylated with iodoacetic acid) a mixture of the two proteins was subjected to PAGE. Only a single band of protein was observed, which indicated that the electrophoretic mobility of the AFp was indistinguishable from that of TTR. Table I shows the results of amino acid analyses of samples of the material in both peak I and in peak II, and of normal TTR, which were carried out together under the same conditions. The amino acid composition of peak II protein (AFp) was very similar to that of normal TTR.
Since the AFp protein closely resembled human TTR in several ways (ability to bind to RBP, electrophoretic mobility), we set out to explore whether the AFp protein, like TTR, also formed a tetrameric structure. To this end, the AFp preparation was examined by SDS-PAGE under nondissociating conditions, where normal TTR (and plasma TTR from patients with FAP [8] ) migrates as the undissociated tetramer. Under these conditions, AFp migrated as a band of protein of -50,000 mol wt. Thus, the AFp protein appeared to form a stable tetramer under conditions where plasma TTR is normally found in tetrameric form. To explore further whether the AFp protein forms a tetrameric structure similar to that of plasma TTR, the ability of the AFp protein to bind thyroxine was examined. It has been
shown that the TTR subunits are organized in the tetramer by extensive hydrogen bonding and hydrophobic contacts, giving rise to a molecule with a channel running through the center of its long axis (37 followed by peaks ofradioactive iodide and then of free hormone (eluted with NaOH). However, when the assay was carried out in the presence of excess unlabeled T4, the protein-bound radioactivity was fully displaced (solid circles, Fig. 2 A) . Parallel experiments (not shown) using the same conditions, but with plasma TTR (reduced and alkylated) as the protein, were performed. Very similar results were obtained.
To further document the binding of T4 to AFp, the labeled material that eluted in fraction 5 (Fig. 2 A) was subjected to PAGE. The resulting gel was sliced from top to bottom and all slices were assayed for 1251 The results are shown in Fig. 2 B. A sharp peak of radioactivity was observed in the gel, corresponding in location to the position of human TTR (reduced and carboxymethylated), which was treated by identical procedures. Thus, this experiment (Fig. 2 ) demonstrated that the AFp protein has the capacity of forming tetramers which manifest binding properties for T4 similar to those shown by normal TTR.
Studies were also conducted on the amyloid fibril protein that did not bind to the RBP affinity column. Amino acid analysis revealed that only approximately one fourth of the total mass ofthis material consisted ofprotein; the nature ofthe nonprotein component(s) is not known. The amino acid composition of the protein was, however, similar to that of TTR (see Table I ). Analysis of this material by SDS-gel electrophoresis (see Appendix for details) showed several protein bands: major bands of molecular weights of ' 15,000 and 32,000, and minor bands of -42,000 and 54,000; higher weight bands were seen as well.
Immunoblotting (see Appendix) demonstrated that all of these protein bands displayed TTR immunoreactivity. The results suggest that these protein bands all represented polymers of a TTR-related subunit, and that TTR-related protein may be the predominant, or almost the sole, protein component of the amyloid fibril. (9), a tryptic peptide map was constructed for N-TTR, by digesting the reduced and carboxymethylated protein with trypsin, separating the fragments by HPLC, and identifying the peptide peaks by their amino acid composition (determined by amino acid analysis). Fig. 3 shows the separation of all tryptic peptides on a C18 reverse-phase column, by using a phosphoric acid-acetonitrile solvent system (system 1). The nomenclature is the same as that of Kanda et al. (9), on the basis of the amino acid sequence of TTR. As shown in Fig. 3 , all the tryptic peptides were separated by HPLC under these conditions. Peptides 4 and 10 eluted as a doublet peak; for preparative purposes, complete separation of these peptides could be achieved by rechromatography on the same column, in the TFA-propanol solvent system (system la) as shown in the inset in Fig. 3 trypsin were further compared with those obtained by tryptic digestion of N-TTR, by analyzing the tryptic digests by HPLC in a different solvent system (system 2, see Methods), with postcolumn fluorescence derivatization. With this system, only the lysine-containing peptides were detected, because oftheir higher reactivity with the o-PA reagent than the arginine peptides and because of the very small quantities of digests used. However, since only 3 ofthe 10 major tryptic peptides ofTTR are argininecontaining peptides, system 2 gave useful information on the comparative chromatographic properties of the three preparations. Identical comparative tryptic peptide maps were observed for the lysine-containing peptides for the three different protein preparations in this second solvent system (data not shown). Thus, with two different solvent systems, the three proteins appeared to yield identical peptides on tryptic digestion, except for the specific differences noted in Figs. 4 and 5. These findings strongly suggest that the structures of the three proteins are largely identical, except for features responsible for the specific peptide differences seen.
Comparative kinetics oftrypsin digestion. The structures of the three proteins (N-TTR, FAP-TTR, and AFp) were compared further by comparing the rates at which different tryptic peptides appeared during digestion under identical conditions and at the same time. Samples of each of the three proteins were concurrently digested with trypsin, and portions of the digests were withdrawn after intervals varying from 15 to 90 min. The samples were analyzed by HPLC, and the relative amounts ofthe different tryptic peptides present in the digests were quantitated. gested or partially digested TTR) was measured by an automatic integrator. For a given analysis, all peak areas werẽ * summed and the total considered to represent 100%. Thẽ xl2+13 area of each peptide peak was divided by the total sum of peak areas, to determine the percentage of peak area values plotted on the ordinate. In this figure, the number to 90 the right of each plotted curve identifies which tryptic peptide is represented by the data points on the curved line.
for this study. As seen in Fig. 6 , the patterns of appearance of the different individual tryptic peptides were generally similar for all three proteins. As discussed above, the "abnormal" peptide (asterisk) was readily observed in the AFp digests, appeared in very small quantities in the FAP-TTR digests, and was not present in the N-TTR digests. Tryptic peptide 4 (TP-4) was absent from the AFp digests, and present in the TTR digests.
The curves for peptides 12 + 13 and 11 + 12 + 13 decreased with time in a more pronounced manner than the curves obtained for the other peptides; this fact is related to chymotryptic cleavage that we observed to occur in tryptic peptide 12. These results further support the conclusion that was suggested from the comparative peptide mapping studies (Figs. 4 and 5) , namely that the primary structures of the three proteins are probably identical except for differences connected with TP-4 and the "abnormal" peptide seen in the preparations from patients with FAP.
Analysis oftryptic peptide T*. Since the "abnormal" peptide (marked with an asterisk) eluted after peptide 4, which was absent from the AFp tryptic digest, we suspected that the abnormal peptide might be closely related to TP-4. Accordingly, the individual tryptic peptides eluting from the HPLC column were collected and subjected to amino acid analysis. Table II shows the amino acid compositions ofTP-4 collected after HPLC separation of N-TTR and FAP-TTR digests, and of the asterisk-labeled peptide collected after HPLC separation of AFp digests. The microscale level at which these latter peptides were analyzed (4-5 ,ug), together with possible small contamination with trypsin autodigestion products, probably contributes to the appearance of contaminating residues observed in all three proteins analyzed (Table II) . The composition of the abnormal peptide (T*) closely resembled the composition of TP-4 from both N and FAP TTR preparations. A prominent difference was the presence of methionine, which was not seen in any of the TP-4 analyses.
The T* peptide was further examined by determining its carboxy-terminal sequence, in order to further document its close relationship to TP-4 (see Appendix for details). This sequencing study indicated that the carboxy-terminal sequence of the "abnormal" tryptic peptide T* is: . . . His-Val-Phe-Arg-COOH. This is also the COOH-terminal sequence for the normal peptide 4, documenting the close relationship between TP-4 and T*.
Cyanogen bromide cleavage. The apparent presence of methionine in peptide T* (Table II) was consistent with the finding that the overall amino acid composition of AFp showed a higher content of methionine than did that of normal TTR (see Table  I ). Normal TTR possesses only one methionine residue, at position 13. CNBr treatment, therefore, cleaves the protein into two peptide fragments: a small peptide, residues 1-13 (called peptide C,), and a large peptide, residues 14-127 (called peptide C2). We reasoned that ifanother methionine residue was present in AFp in the region of TP-4 (residues 22-34), CNBr treatment of AFp would produce extra peptide fragments (as compared with TTR). Accordingly, samples of AFp were subjected to CNBr treatment, followed by HPLC analysis and separation of the resulting peptide fragments. Samples of N-TTR and of FAP-TTR were treated and analyzed in an identical manner for comparative purposes. Fig. 7 shows the comparative HPLC peptide maps obtained for each of the three proteins after CNBr cleavage. When intact TTR was analyzed under the same gradient conditions it eluted at the end of the gradient, mainly as a major peak at 66 min and a minor peak at 70 min.
N-TTR (Fig. 7, top Normal TTR contains a cysteine residue at position 11; accordingly, since the N-TTR and FAP-TTR protein preparations had previously been alkylated with [3H]iodoacetic acid, fragment C1 would be expected to be radioactive. The fractions eluted from the HPLC column were, therefore, collected and assayed for 3H-radioactivity. Radioactivity was detected at the beginning of the gradient, overlapping the early group of small peaks, with retention time of -10-12 min. Radioactivity was also detected in late fractions corresponding to uncleaved TTR. More definitive identification of the CNBr fragments was achieved by amino acid analysis. Fragment Cl was identified in the fractions overlapping the radioactive peak (eluting at 10-13 mmn), both in the N-TTR and FAP-TTR preparations.
In the AFp profile shown in Fig. 7 (bottom tracing), this fragment (Cl) is not evident. However, in three other experiments carried out with AFp over the course of this work, this peptide was evident on the chromatograms.
With N-TTR, the material eluting in the later, overlapping peaks at -~.35-55 mmn was identified by amino acid analysis as fragment (peptide) C2 (see Table III ). This fragment (C2) hence showed elution heterogeneity, probably due to amide differences and aggregation phenomena. The fractions corresponding to peptides Cl and C2 are so labeled in the top panel of Fig. 7 .
In contrast to normal TTR, after CNBr cleavage of FAP-TTR or of AFp, the HPLC peptide maps showed two sharp peptide peaks eluting at 21 and at 22 minutes (Fig. 7, middle and bottom panels, see peaks labeled Ca and Ci+a). These peaks were consistently found with FAP-TTR (five experiments) and with AFp (four experiments), and were never seen with N-TTR.
These peakcs were collected and subjected to amino acid analysis.
Homoserine lactone (Hsl in Table III) was found with both peaks, indicating that they both represented CNBr cleavage peptides with COOH-terminal methionine residues. The amino acid composition of the first peak (Ca in Fig. 7 ), eluting at 21 min in the chromatogram, was very similar to that of a hypothetical peptide composed of residues [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , which would be generated by the presence ofa methionine residue at position 30 (see Table  III ). The second extra peak, eluting at 22 min of the gradient, showed, on amino acid analysis, methionine and methionine sulfoxide (Met(o) in Table III ) and carboxymethylcysteine; this peak also showed 3H-radioactivity. The amino acid composition ofthis peptide (Table III) resembled that of a peptide composed of residues with a methionine at position 30 and with an uncleaved methionine at position 13. This peak is, therefore, referred to as peptide C,+a.
If AFp (and in part FAP-TTR) contains a methionine residue at position 30, one would also expect to find a peptide fragment corresponding to residues 31-127 after CNBr cleavage. This "extra" CNBr fragment, which we refer to as peptide Cb, was not evident in the HPLC chromatograms (Fig. 7) . We suspected, however, that this peptide was coeluting with uncleaved fragment C2. Evidence for this conclusion came from the amino acid analysis of fractions from the AFp preparation eluting in the normal position ofthe C2 peptide (see Table III ). These fractions from AFp showed differences from the corresponding fractions from N-TTR, particularly decreases in valine and alanine content (which appear in relatively high amounts in peptide Ca), consistent with their being a mixture of C2 and Cb.
To verify this hypothesis, SDS-PAGE was carried out on pooled fractions corresponding to the normal peptide C2 (from N-TTR), and on pooled fractions from the AFp preparation eluting at approximately the same position. The results are shown in Fig. 8 that the oxidation of methionine to methionine sulfoxide is a side reaction of the CNBr cleavage itself, and may, therefore, interfere with the reaction (39). The fact that both methionine and methionine sulfoxide were detected in fractions corresponding to peptide C2 in the AFp preparation, however, in contrast with the normal composition of C2, corroborated the hypothesis of the presence of an extra methionine in AFp.
The results obtained from these CNBr cleavage studies, therefore, supported the hypothesis that the AFp protein differed from normal TTR by having a methionine residue at position 30. Evidence in support of this conclusion was then obtained by microsequencing studies of both peptide Ca and of Cb (see Appendix for details).
NH2-terminal sequence analysis of peptide Ca, for five analyzed positions, indicated that its sequence corresponds to the NH2-terminal sequence of normal peptide C2, residues 14-18 of TTR (see Fig. 9 cycle and a large yield of phenylalanine was found in the third cycle. These residues presumably represent the second and the third NH2-terminal residues ofCb, corresponding to Val-32 and Phe-33 of TTR (see Fig. 9 ). Thus, these data further support the conclusion that AFp has a Met at position 30 , and that CNBr cleavage of AFp yields peptides C, (residues 1-13), Ca (residues 14-30), and Cb (residues 31-127). (Fig. 6 ). in its properties. Since the isolated AFp protein resembled plasma TTR in forming a stable tetrameric structure, and in its binding affinity for both RBP and thyroxine, we can conclude that the methionine-for-valine substitution at position 30 in AFp does not substantially alter any of those aspects of the structure of TTR that are involved in formation of the tetrameric structure, or in the interactions of TTR with RBP or thyroxine.
The structure of the TTR subunit is dominated by eight f-strands, into which -50% of the amino acids are organized, as two four-stranded p3-sheets (37) . The sheets are labeled A to H, according to their position in the sequence, and form two sheets, DAGH and CBEF, whose hydrogen bond interactions are predominantly antiparallel (37 (37) . The close stereochemical relationship of residues 30 and 49, the two residues now found to be substituted in TTR-related amyloid proteins, raises the possibility that these residues are part of a structural domain which, ifaltered, is critically involved in the pathogenesis of FAP. The possibility that such a domain might be important in some as yet unknown aspect of TTR metabolism can also be considered. For example, it has been suggested that TTR may play some specific role in the peripheral nervous system (45) . It has also been suggested that a circulating abnormal TTR molecule in FAP patients might be toxic to peripheral nerve tissues even before it is aggregated into sizable amyloid deposits (6) . In this regard it should be noted that peripheral nerve fiber changes have been observed in some asymptomatic children of Portuguese patients with FAP (46 Both normal TP-4 and the variant peptide T* were observed in the peptide maps of TTR from pooled sera of FAP patients.
In several peptide mapping studies carried out with FAP-TTR, during the course of this work, the normal TP-4 was approximately four to six times more abundant than the aberrant peptide T*. Thus, in these patients, two forms of TTR subunits (present as tetrameric TTR molecules) circulated in plasma, the variant TTR subunit with a methionine-for-valine substitution at position 30, and a larger amount (four to six times) of normal TTR. It is likely that these patients were genetically heterozygous with respect to TTR, and had two TTR alleles, one coding for the normal TTR subunit and the other for the variant TTR subunit. Very recently, after the initial presentation (12) of the present work, a brief communication appeared reporting the presence of a variant TTR in plasma with the same structural alteration (methionine for valine at position 30) as that described here, in a patient of Swedish origin with FAP (47). It is not yet known whether, in these Swedish patients, this variant TTR is also the amyloid fibril protein that deposits in their tissues; earlier studies on amyloid fibril protein from the same kindred (4) suggested that other differences in primary structure, compared with that of TTR, were present. In the present work, the reason for the relatively reduced amount of the variant TTR, compared with that of normal TTR, in FAP serum, has not been determined. One explanation might be a reduced rate of synthesis of the variant as compared with the normal TTR subunit (i.e., reduced gene expression of the allele for the variant TTR subunit). Alternatively, both TTR subunits might be produced at similar rates, with several forms of hybrid TTR tetramers circulating in plasma, but a particular species containing the variant TTR might be removed more rapidly than normal TTR from plasma, either because of more rapid degradation and/or its deposition in tissues. Any of these possibilities would be consistent with our previous finding (8) (48, 49) , in which it has been shown that the Rhesus TTR is under the control of two autosomal codominant alleles. We believe that this latter possibility is unlikely for the human, particularly since two different variants ofTTR (12, 44) (present work) have now been found specifically as components of amyloid fibril protein in FAP.
Although slightly different phenotypic clinical expressions exist among the different ethnic and geographic varieties of FAP, these syndromes all exhibit prominent peripheral neuropathy (1) . Future studies are needed to determine whether or not these different varieties of FAP represent different mutations in the TTR molecule. That genetic heterogeneity at the TTR locus can occur in FAP of autosomal dominant inheritance, whereby different mutations on the same molecule produce a similar clinical picture, is indicated by the studies ofthe amyloid protein of a Jewish patient with FAP (44) along with the work on Portuguese patients reported here. Studies ofamyloid proteins and serum TTR from FAP patients of other origins are needed in order to further define the extent of possible genetic heterogeneity. The methodology presented here could be applied effectively to this problem, by using comparative HPLC mapping oftryptic peptides to screen for possible alterations in the primary structure of TTR in the different varieties of FAP. In addition, these methods could be used to screen family members of FAP patients as to whether or not the variant TTR is present in their plasma. We are currently engaged in such studies on TTR from individual FAP patients and their asymptomatic children, in order to try to define whether or not the presence of the TTR variant can be used as a preclinical biochemical marker of the disease. Such a marker might ultimately be important in attempts at prevention or early treatment of this disease.
Appendix
This Appendix provides the detailed results of the studies carried out concerning the peak I protein from the solubilized amyloid fibrils, and of the microsequencing studies carried out on the AFp (peak II) protein.
PAGE and immunological analyses ofthe solubilized amyloidfibril. Fig. 10 A (left-hand panel) shows the results of SDS-PAGE analysis of the material eluted in peaks I and II from the RBP-Sepharose affinity column. The conditions used were those in which normal TTR (reduced and carboxymethylated) is mostly dissociated into monomeric subunits, with a small amount of dimer being present. The peak II material (AFp protein) migrated as a major band of molecular weight -15,000, and a minor band of -32,000 mol wt (Fig. 10 A, gel 2) . Hence, as discussed above, AFp protein showed electrophoretic properties that were virtually identical to those of TTR.
In contrast, peak I material showed several bands ofprotein on SDS-PAGE under the same conditions ( Fig. 10 A, gel 1 At the indicated times, samples were withdrawn from the incubation mixture, and were immediately injected into the HPLC for detection and quantitation of the released amino acids, using precolumn fluorescence derivatization (see Methods) to achieve high sensitivity. After subtraction of the blank values (see Methods) the amounts of the released amino acids were plotted versus time of digestion. of peptide C. was performed by manual Edman microsequence analyses (see Methods). The phenylthiohydantoin-amino acid derivatives were hydrolyzed and the free amino acids quantitated by amino acid analysis using precolumn derivatization. Table IV Table V shows the amounts of the individual amino acids obtained after three cycles of degradation. With the normal C2 peptide, an NH2-terminal sequence of H2N-ValLys-Val . . . was obtained, corresponding to the expected sequence for residues 14, 15, and 16 of TTR (see Fig. 9 ). With the preparation from the AFp protein, however, in addition to the residues expected for the NH2-terminal sequence of peptide C2, other residues were also found Fig. 7 were used for these analyses. Peptide Nc was the purified C2 peptide derived from pooled fractions of the N-TTR preparation, labeled C2 in Fig.  7 , top tracing. Peptide Ac was a mixture of peptides C2 + Cb derived from the pooled fractions of the AFp preparation labeled C2 + Cb in Fig. 7 , bottom tracing.
in the second and third cycles. Thus, in the second cycle valine was found in addition to lysine, consistent with it representing Val 32 of TTR (second NH2-terminal residue of Gb) (see Fig. 9 ). The recoveries of this cycle were, however, very low, which is not uncommon when manual techniques are used. The results ofthe third cycle were, however, definitive, with a large yield ofPhe, representing Phe 33, being obtained.
